Back to Search
Start Over
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.
- Source :
-
Leukemia research [Leuk Res] 2013 Aug; Vol. 37 (8), pp. 868-71. Date of Electronic Publication: 2013 May 31. - Publication Year :
- 2013
-
Abstract
- Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of acute myeloid leukemia (AML). Drug shortages have required the substitution of daunorubicin with idarubicin. Randomized studies have shown idarubicin (10-12mg/m(2)) to be comparable or superior to standard dose daunorubicin (45-60mg/m(2)) for achieving complete remission (CR). Whether these results can be extrapolated to dose-intense daunorubicin (90mg/m(2)), recently shown to improve CR rates when compared to standard daunorubicin doses remains uncertain. This observational study was conducted at Northwestern Memorial Hospital (NMH) to compare CR rates. The results suggest idarubicin is equivalent to daunorubicin, and for some subsets of patients, idarubicin may have superior CR rates.<br /> (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Subjects :
- Acute Disease
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Biological Availability
Daunorubicin administration & dosage
Daunorubicin pharmacokinetics
Dose-Response Relationship, Drug
Female
Humans
Idarubicin administration & dosage
Idarubicin pharmacokinetics
Kaplan-Meier Estimate
Leukemia, Myeloid metabolism
Leukemia, Myeloid pathology
Male
Middle Aged
Outcome Assessment, Health Care
Remission Induction
Young Adult
Daunorubicin therapeutic use
Idarubicin therapeutic use
Leukemia, Myeloid drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5835
- Volume :
- 37
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Leukemia research
- Publication Type :
- Academic Journal
- Accession number :
- 23726414
- Full Text :
- https://doi.org/10.1016/j.leukres.2013.04.009